A. Millier

1.7k total citations
86 papers, 1.2k citations indexed

About

A. Millier is a scholar working on Economics and Econometrics, Psychiatry and Mental health and Philosophy. According to data from OpenAlex, A. Millier has authored 86 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Economics and Econometrics, 26 papers in Psychiatry and Mental health and 14 papers in Philosophy. Recurrent topics in A. Millier's work include Health Systems, Economic Evaluations, Quality of Life (34 papers), Schizophrenia research and treatment (25 papers) and Pharmaceutical Economics and Policy (15 papers). A. Millier is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (34 papers), Schizophrenia research and treatment (25 papers) and Pharmaceutical Economics and Policy (15 papers). A. Millier collaborates with scholars based in France, Germany and United Kingdom. A. Millier's co-authors include Mondher Toumi, Samuel Aballéa, Matthias C. Angermeyer, J Brière, Ulrike Schmidt, Pierre Lévy, M C Angermeyer, V. Murthy, Kevin Bowrin and Pascal Auquier and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and The British Journal of Psychiatry.

In The Last Decade

A. Millier

82 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. Millier France 19 432 279 273 264 136 86 1.2k
Alexandra Ward United States 21 396 0.9× 96 0.3× 298 1.1× 61 0.2× 119 0.9× 52 1.9k
John D. Goodson United States 11 326 0.8× 120 0.4× 147 0.5× 56 0.2× 86 0.6× 36 1.4k
Juha Mehtälä Finland 15 1.1k 2.7× 312 1.1× 90 0.3× 171 0.6× 98 0.7× 48 1.6k
Ben Wijnen Netherlands 18 320 0.7× 150 0.5× 220 0.8× 86 0.3× 29 0.2× 92 1.0k
Jan Sermon Belgium 11 839 1.9× 279 1.0× 112 0.4× 154 0.6× 22 0.2× 26 1.2k
Mark P. Hanna United States 14 260 0.6× 195 0.7× 110 0.4× 239 0.9× 130 1.0× 20 1.4k
Diana Rofail United States 16 195 0.5× 118 0.4× 89 0.3× 59 0.2× 44 0.3× 43 1.2k
Barbara Stein Germany 17 145 0.3× 213 0.8× 59 0.2× 127 0.5× 28 0.2× 56 801
Jan McKendrick United States 13 247 0.6× 64 0.2× 74 0.3× 103 0.4× 36 0.3× 26 640
Joseph Wanderling United States 15 478 1.1× 324 1.2× 39 0.1× 189 0.7× 24 0.2× 41 1.1k

Countries citing papers authored by A. Millier

Since Specialization
Citations

This map shows the geographic impact of A. Millier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Millier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Millier more than expected).

Fields of papers citing papers by A. Millier

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Millier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Millier. The network helps show where A. Millier may publish in the future.

Co-authorship network of co-authors of A. Millier

This figure shows the co-authorship network connecting the top 25 collaborators of A. Millier. A scholar is included among the top collaborators of A. Millier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Millier. A. Millier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cherney, David Z.I., Aleksandra Drzewiecka‐Antonik, Kerstin Folkerts, et al.. (2025). Cost-effectiveness of finerenone therapy for patients with chronic kidney disease and type 2 diabetes in England & Wales: results of the FINE-CKD model. Journal of Medical Economics. 28(1). 196–206. 3 indexed citations
2.
Millier, A., Samuel Aballéa, C. François, et al.. (2024). Cost-effectiveness of ten commonly used antipsychotics in first-episode schizophrenia in the UK: economic evaluation based on a de novo discrete event simulation model. The British Journal of Psychiatry. 227(2). 545–552.
3.
Folkerts, Kerstin, et al.. (2022). Real-world evidence for steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease. Journal of Nephrology. 36(4). 1135–1167. 4 indexed citations
4.
Escobar, Carlos, Julio Martí‐Almor, Alejandro Pérez Cabeza, et al.. (2022). Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain. PLoS ONE. 17(4). e0266658–e0266658. 9 indexed citations
5.
6.
Bowrin, Kevin, J Brière, Laurent Fauchier, et al.. (2020). Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France. PLoS ONE. 15(1). e0225301–e0225301. 10 indexed citations
7.
Bowrin, Kevin, J Brière, Pierre Lévy, Mondher Toumi, & A. Millier. (2020). Use of real-world evidence in meta-analyses and cost-effectiveness models. Journal of Medical Economics. 23(10). 1053–1060. 5 indexed citations
8.
9.
Toumi, Mondher, A. Millier, C. Rémuzat, et al.. (2017). Analysis of health economics assessment reports for pharmaceuticals in France – understanding the underlying philosophy of CEESP assessment. SHILAP Revista de lepidopterología. 5(1). 1344088–1344088. 18 indexed citations
10.
Chouaïd, C., Delphine Loirat, E. Clay, et al.. (2017). P1.06-044 Costs of Adverse Events (AE) Associated with Cancer Therapies in Non-Small Cell Lung Cancer (NSCLC) in France. Journal of Thoracic Oncology. 12(1). S693–S693. 1 indexed citations
11.
Chouaïd, C., et al.. (2016). Costs of Adverse Events Associated with Cancer Therapies in Non-Small Cell Lung Cancer in France. Value in Health. 19(7). A743–A743. 2 indexed citations
12.
Pontes, Caridad, et al.. (2015). Safety and Activity of UR-1505 in Atopic Dermatitis: A Randomized, Double-blind Phase II Exploratory Trial. Clinical Therapeutics. 37(9). 1955–1965. 2 indexed citations
13.
Angermeyer, Matthias C., et al.. (2014). Biogenetic explanations and emotional reactions to people with schizophrenia and major depressive disorder. Psychiatry Research. 220(1-2). 702–704. 9 indexed citations
14.
Weil-Olivier, Catherine, et al.. (2014). Population access to rotavirus vaccination in industrialized countries: lessons learnt from current experience. Expert Review of Vaccines. 13(11). 1405–1417. 1 indexed citations
15.
Angermeyer, Matthias C., et al.. (2014). Continuum beliefs and attitudes towards people with mental illness: Results from a national survey in France. International Journal of Social Psychiatry. 61(3). 297–303. 35 indexed citations
16.
Millier, A., et al.. (2014). Minimum Clinically Important Difference in the Calgary Depression Scale for Schizophrenia. Value in Health. 17(7). A766–A766. 3 indexed citations
17.
Millier, A., et al.. (2014). Social Contacts Reduce Negative Symptoms, Especially Emotional Withdrawal in Patients with Schizophrenia. Value in Health. 17(7). A455–A455. 2 indexed citations
18.
Angermeyer, Matthias C., et al.. (2013). Attitudes and beliefs of the French public about schizophrenia and major depression: results from a vignette-based population survey. BMC Psychiatry. 13(1). 313–313. 51 indexed citations
19.
Angermeyer, Matthias C., Georg Schomerus, Mauro Giovanni Carta, et al.. (2013). Burnout: Ein deutsches Phänomen?. Psychiatrische Praxis. 40(8). 425–429. 16 indexed citations
20.
Millier, A., et al.. (2012). PMH45 Health-Related Quality of Life Patient-Reported Outcomes in Schizophrenia. Value in Health. 15(7). A342–A342. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alexandra Ward Breakdown of academic impact, for papers by John D. Goodson Breakdown of academic impact, for papers by Juha Mehtälä Breakdown of academic impact, for papers by Ben Wijnen Breakdown of academic impact, for papers by Jan Sermon Breakdown of academic impact, for papers by Mark P. Hanna Breakdown of academic impact, for papers by Diana Rofail Breakdown of academic impact, for papers by Barbara Stein Breakdown of academic impact, for papers by Jan McKendrick Breakdown of academic impact, for papers by Joseph Wanderling
Rankless by CCL
2026